论文信息 - Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing - 字舞流文

Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing

G. Song | Jianfeng Xiao | Jianfeng Chen | Lin Wang | J. Lou | Qiaomei Guo | Wen-jun Yu | Xiaomeng Hu | Junlei Wang

[1] K. Pienta,et al. Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests , 2017, JAMA oncology.

[2] Sam Angiuoli,et al. Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[3] G. Lyman,et al. Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology , 2017, JAMA oncology.

[4] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[5] Ashwini Naik,et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[6] Pingfang Liu,et al. DNA damage is a pervasive cause of sequencing errors, directly confounding variant identification , 2017, Science.

[7] L. Platanias,et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA , 2016, Oncotarget.

[8] B. Kermani,et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[9] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.

[10] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.